Shares of Laboratory Corp. of America Holdings (NYSE:LH) reached a new 52-week low on Thursday . The stock traded as low as $139.18 and last traded at $141.57, with a volume of 62844 shares changing hands. The stock had previously closed at $143.33.

LH has been the topic of several research reports. Zacks Investment Research cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. Credit Suisse Group cut their price objective on Laboratory Corp. of America from $197.00 to $195.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 4th. Morgan Stanley lifted their price objective on Laboratory Corp. of America from $192.00 to $202.00 and gave the company a “buy” rating in a research report on Monday, September 10th. Citigroup dropped their price target on Laboratory Corp. of America from $184.00 to $171.00 and set a “neutral” rating on the stock in a research report on Thursday, October 25th. Finally, William Blair reissued an “outperform” rating on shares of Laboratory Corp. of America in a research report on Wednesday, October 24th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Laboratory Corp. of America has a consensus rating of “Hold” and a consensus price target of $179.69.

The company has a debt-to-equity ratio of 0.83, a current ratio of 1.55 and a quick ratio of 1.44. The stock has a market capitalization of $14.46 billion, a P/E ratio of 14.96, a P/E/G ratio of 1.47 and a beta of 0.99.

Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.74 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.14). Laboratory Corp. of America had a return on equity of 17.13% and a net margin of 13.27%. The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.84 billion. During the same period in the prior year, the firm earned $2.46 earnings per share. The business’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, equities analysts anticipate that Laboratory Corp. of America Holdings will post 10.99 EPS for the current year.

In related news, Director Kerrii B. Anderson sold 3,700 shares of the business’s stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $163.29, for a total value of $604,173.00. Following the completion of the transaction, the director now directly owns 21,795 shares in the company, valued at approximately $3,558,905.55. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director R Sanders Williams sold 350 shares of the business’s stock in a transaction that occurred on Tuesday, November 27th. The stock was sold at an average price of $162.14, for a total transaction of $56,749.00. Following the completion of the transaction, the director now owns 7,886 shares of the company’s stock, valued at $1,278,636.04. The disclosure for this sale can be found here. 0.73% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Captrust Financial Advisors raised its holdings in Laboratory Corp. of America by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 1,785 shares of the medical research company’s stock worth $320,000 after acquiring an additional 297 shares during the last quarter. Piedmont Investment Advisors Inc. raised its holdings in Laboratory Corp. of America by 24.8% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 1,493 shares of the medical research company’s stock worth $259,000 after acquiring an additional 297 shares during the last quarter. State Treasurer State of Michigan raised its holdings in Laboratory Corp. of America by 1.0% in the 2nd quarter. State Treasurer State of Michigan now owns 30,297 shares of the medical research company’s stock worth $5,439,000 after acquiring an additional 300 shares during the last quarter. Alps Advisors Inc. raised its holdings in Laboratory Corp. of America by 11.1% in the 2nd quarter. Alps Advisors Inc. now owns 3,057 shares of the medical research company’s stock worth $549,000 after acquiring an additional 305 shares during the last quarter. Finally, Strs Ohio raised its holdings in Laboratory Corp. of America by 1.3% in the 3rd quarter. Strs Ohio now owns 24,261 shares of the medical research company’s stock worth $4,213,000 after acquiring an additional 311 shares during the last quarter. Institutional investors own 91.68% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Laboratory Corp. of America (LH) Sets New 12-Month Low at $139.18” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/laboratory-corp-of-america-lh-sets-new-12-month-low-at-139-18/2665885.html.

Laboratory Corp. of America Company Profile (NYSE:LH)

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Recommended Story: What is dollar cost averaging (DCA)?

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.